Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007201
Chunk: 111

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 111
---
4.99% beneficial ownership limitation, if applicable. The principal business address of Brio Capital      
 Master Fund Ltd. is c/o Brio Capital Management LLC, 100 Merrick Road, Suite 401W, Rockville Centre, NY 11570.                            |

| (4) | The selling                                                                                                                                   
 shareholder holds (i) warrants issued by us in prior transactions which entitle the selling shareholder                                       
 to purchase an aggregate of 728,230,000 Ordinary Shares (in the form of Depositary Shares), and (ii) Series                                   
 J Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 425,530,000 Ordinary Shares (in the form of         
 Depositary Shares) and Series K Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 425,530,000 Ordinary  
 Shares (in the form of Depositary Shares) and which we are registering hereby. The warrants are subject to a beneficial ownership limitation  
 of 4.99%, which does not permit the selling shareholder to exercise that portion of the warrants that would result in the selling shareholder 
 and its affiliates owning, after exercise, a number of our Ordinary Shares in excess of the beneficial ownership limitation. The amounts      
 and percentages in the table do not give effect to the 4.99% beneficial ownership limitation, if applicable. The principal business address   
 of Cavalry Fund I LP is 82 E. Allendale Road, Suite 5B, Saddle River, NJ 07458.                                                               |

| 71 |

| (5) | The selling shareholder holds (i)                                                                                                          
 warrants issued by us in prior transactions which entitle the selling shareholder to purchase an aggregate of 453,050,000 Ordinary Shares  
 (in the form of Depositary Shares), and (ii) Series J Warrants issued by us which entitle the selling                                      
 shareholder to purchase an aggregate of 212,760,000 Ordinary Shares (in the form of Depositary Shares) and Series K Warrants issued by     
 us which entitle the selling shareholder to purchase an aggregate of 212,760,000 Ordinary Shares (in the form of Depositary Shares) and    
 which we are registering hereby. The warrants are subject to a beneficial ownership limitation of 9.99%, which does not permit             
 the selling shareholder to exercise that portion of the warrants that would result in the selling shareholder and its affiliates owning,   
 after exercise, a number of our Ordinary Shares in excess of the